OVERVIEW

Implementing New Pharmacologic Treatments to Achieve Optimal Outcomes in Patients with Multiple Myeloma is organized by AcademicCME. This Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits™ / 1.0 CNE Contact Hour

Start Date: September 23, 2019
Expiry Date: September 22, 2020

Target Audience:
Oncologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with multiple myeloma.

Program Overview:
This CME/CE activity will highlight recent data for the treatment and management of multiple myeloma (MM), including information presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. The expert faculty, chaired by C. Ola Landgren, MD, PhD, will first discuss the pathophysiology of multiple myeloma, reviewing the skeletal, renal, hematologic and neurologic processes in a case-based format. Current clinical trial data of approved therapeutic options as well as emerging agents will be reviewed, and clinical relevance debated. The faculty will cover best practices for improving quality of life and adherence to therapy through personalized medicine utilizing the interprofessional team. This CME/CE activity will update healthcare professionals on best practices for providing optimal, comprehensive care in multiple myeloma.

Learning Objectives:
• Discuss the skeletal, renal, hematologic, and neurologic processes to understand the pathophysiology of multiple myeloma
• Analyze clinical data of new pharmacologic treatments to improve quality of life in patients with multiple myeloma, including data presented at ASCO 2019
• Create effective treatment regimens with the healthcare team to achieve optimal outcomes and manage patients with multiple myeloma